Warning: The NCBI web site requires JavaScript to function. more...
Imaging in breast cancer - breast cancer imaging revisited.
Mankoff D.
Breast Cancer Res. 2005;7(6):276-8. Epub 2005 Nov 29. No abstract available.
Related citations
Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography.
Bénard F, Turcotte E.
Breast Cancer Res. 2005;7(4):153-62. Epub 2005 May 12. Review.
18F-FDG PET in detecting primary breast cancer.
Kumar R, Lal N, Alavi A.
J Nucl Med. 2007 Oct;48(10):1751; author reply 1752. No abstract available.
Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour.
Beresford M, Sanghera B, Wong WL, Makris A.
Eur J Nucl Med Mol Imaging. 2006 May;33(5):624. Epub 2006 Feb 28. No abstract available.
Hybrid PET-dynamic CECT in the management of breast cancer.
Kumar R, Das CJ.
Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):413-5. Review. No abstract available.
FDG PET, PET/CT, and breast cancer imaging.
Rosen EL, Eubank WB, Mankoff DA.
Radiographics. 2007 Oct;27 Suppl 1:S215-29. Review.
Primer on imaging technologies for cancer.
Schnall M, Rosen M.
J Clin Oncol. 2006 Jul 10;24(20):3225-33. Review.
Should FDG PET/CT be used for the initial staging of breast cancer?
Groheux D, Hindié E, Rubello D, Espié M, Baillet G, Giacchetti S, Misset JL, Moretti JL.
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1539-42. Review. No abstract available.
PET-CT imaging in the initial management of high-risk breast cancer patients: who did it help?
Pugliese M, Shivaram G, Rogers J, Haseley D, Buchanan C.
Breast J. 2009 Sep-Oct;15(5):554-6. Epub 2009 Aug 4. No abstract available.
Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.
Jpn J Clin Oncol. 2008 Apr;38(4):250-8.
Imaging bone metastases in breast cancer.
Hall FM.
AJR Am J Roentgenol. 2005 Oct;185(4):1082; author reply 1082-3. No abstract available.
Molecular imaging in breast cancer.
Schuster DM, Halkar RK.
Radiol Clin North Am. 2004 Sep;42(5):885-908, vi-vii. Review.
F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
Avril N, Adler LP.
Radiol Clin North Am. 2007 Jul;45(4):645-57, vi. Review.
A surgical perspective on positron emission tomography.
Gulec SA.
J Surg Oncol. 2007 May 1;95(6):443-6. No abstract available.
[Imaging methods in the current diagnosis of and screening for breast cancer].
Forrai G, Szabó E, Ormándi K, Ambrózay E, Péntek Z, Milics M, Rajtár M, Sinkovics I.
Magy Onkol. 2010 Sep;54(3):211-6. Hungarian. No abstract available.
Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT.
Korn RL, Yost AM, May CC, Kovalsky ER, Orth KM, Layton TA, Drumm D.
AJR Am J Roentgenol. 2006 Jul;187(1):81-5.
Nuclear imaging in breast cancer.
Ferrara A.
Radiol Technol. 2010 Jan-Feb;81(3):233-46. Review.
Value of fluorodeoxyglucose positron emission tomography in women with breast cancer (Br J Surg 2005; 92: 1363-1367).
Hayanga AJ.
Br J Surg. 2006 Feb;93(2):252; author reply 252-3. No abstract available.
Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET.
Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P.
Clin Nucl Med. 2009 Jul;34(7):417-20.
The search for occult metastatic disease in breast cancer patients: how far should we go?
Newman LA.
Ann Surg Oncol. 2006 May;13(5):604-6. Epub 2006 Mar 13. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on